Marcos Abraao De Souza Fonseca

Dr. Marcos Abraao De Souza Fonseca

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in Science Advances
Verified
Journal Article
Open access
JRJessica Reddy
Jessica Reddy
Marcos Abraao De Souza FonsecaMarcos Abraao De Souza Fonseca
Marcos Abraao De Souza Fonseca
RCRosario I. Corona
Rosario I. Corona
RNRobbin Nameki
Robbin Nameki
FDFelipe Segato Dezem
Felipe Segato Dezem
Kate LawrensonKate Lawrenson
Kate Lawrenson
The CaCTS algorithm nominates cancer cell master transcription factors and guides a model of ovarian cancer regulatory circuitry.

1 September 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
BGBeatriz German
Beatriz German
SASarah A. Alaiwi
Sarah A. Alaiwi
KHKun-Lin Ho
Kun-Lin Ho
JNJagpreet S. Nanda
Jagpreet S. Nanda
Marcos Abraao De Souza FonsecaMarcos Abraao De Souza Fonseca
Marcos Abraao De Souza Fonseca
LELeigh Ellis
Leigh Ellis
Phenotypic plasticity is a recognized mechanism driving therapeutic resistance in patients with prostate cancer. Although underlying molecular causations driving phenotypic plasticity have been identified, therapeutic success is yet to be achieved. To identify putative master regulator transcription factors (MR-TF) driving phenotypic plasticity in prostate cancer, this work utilized a multiomic approach using genetically engineered mouse models of prostate cancer combined with patient data to identify MYB proto-oncogene like 2 (MYBL2) as a significantly enriched transcription factor in prostate cancer exhibiting phenotypic plasticity. Genetic inhibition of Mybl2 using independent murine prostate cancer cell lines representing phenotypic plasticity demonstrated Mybl2 loss significantly decreased in vivo growth as well as cell fitness and repressed gene expression signatures involved in pluripotency and stemness. Because MYBL2 is currently not druggable, a MYBL2 gene signature was employed to identify cyclin-dependent kinase-2 (CDK2) as a potential therapeutic target. CDK2 inhibition phenocopied genetic loss of Mybl2 and significantly decreased in vivo tumor growth associated with enrichment of DNA damage. Together, this work demonstrates MYBL2 as an important MR-TF driving phenotypic plasticity in prostate cancer. Furthermore, high MYBL2 activity identifies prostate cancer that would be responsive to CDK2 inhibition. Significance: Prostate cancers that escape therapy targeting the androgen receptor signaling pathways via phenotypic plasticity are currently untreatable. Our study identifies MYBL2 as a MR-TF in phenotypic plastic prostate cancer and implicates CDK2 inhibition as a novel therapeutic target for this most lethal subtype of prostate cancer.

12 November 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
JRJessica Reddy
Jessica Reddy
Marcos Abraao De Souza FonsecaMarcos Abraao De Souza Fonseca
Marcos Abraao De Souza Fonseca
RCRosario I Corona
Rosario I Corona
RNRobbin Nameki
Robbin Nameki
FDFelipe Segato Dezem
Felipe Segato Dezem
Kate LawrensonKate Lawrenson
Kate Lawrenson
The function of critical developmental regulators can be subverted by cancer cells to control expression of oncogenic transcriptional programs. These "master transcription factors" (MTFs) are often essential for cancer cell survival and represent vulnerabilities that can be exploited therapeutically. The current approaches to identify candidate MTFs examine super-enhancer associated transcription factor-encoding genes with high connectivity in network models. This relies on chromatin immunoprecipitation-sequencing (ChIP-seq) data, which is technically challenging to obtain from primary tumors, and is currently unavailable for many cancer types and clinically relevant subtypes. In contrast, gene expression data are more widely available, especially for rare tumors and subtypes where MTFs have yet to be discovered. We have developed a predictive algorithm called CaCTS (Cancer Core Transcription factor Specificity) to identify candidate MTFs using pan-cancer RNA-sequencing data from The Cancer Genome Atlas. The algorithm identified 273 candidate MTFs across 34 tumor types and recovered known tumor MTFs. We also made novel predictions, including for cancer types and subtypes for which MTFs have not yet been characterized. Clustering based on MTF predictions reproduced anatomic groupings of tumors that share 1-2 lineage-specific candidates, but also dictated functional groupings, such as a squamous group that comprised five tumor subtypes sharing 3 common MTFs. PAX8, SOX17, and MECOM were candidate factors in high-grade serous ovarian cancer (HGSOC), an aggressive tumor type where the core regulatory circuit is currently uncharacterized. PAX8, SOX17, and MECOM are required for cell viability and lie proximal to super-enhancers in HGSOC cells. ChIP-seq revealed that these factors co-occupy HGSOC regulatory elements globally and co-bind at critical gene loci including MUC16 (CA-125). Addiction to these factors was confirmed in studies using THZ1 to inhibit transcription in HGSOC cells, suggesting early down-regulation of these genes may be responsible for cytotoxic effects of THZ1 on HGSOC models. Identification of MTFs across 34 tumor types and 140 subtypes, especially for those with limited understanding of transcriptional drivers paves the way to therapeutic targeting of MTFs in a broad spectrum of cancers.

16 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
YHYungyi Hsiao
Yungyi Hsiao
Marcos Abraao De Souza FonsecaMarcos Abraao De Souza Fonseca
Marcos Abraao De Souza Fonseca
ATAlina S Tiemroth
Alina S Tiemroth
EVEstefany J Vasquez
Estefany J Vasquez
AGAndrea M Gomez
Andrea M Gomez
Summary: Psychedelics engage the serotonergic system as potent neuromodulators, increasing neuroplasticity in humans and rodents. Persistent changes in cognitive flexibility, emotional regulation, and social cognition are thought to underlie the therapeutic effects of psychedelics. However, the underlying molecular and cellular basis of psychedelic-induced plasticity remains unclear. Here, we identify persistent, cell type-specific alternative splicing changes in the mouse medial prefrontal cortex (mPFC) induced by a single dose of psychedelics. Combining deep RiboTag sequencing and bioinformatics, we find that a single dose of psychedelics modestly alters gene expression while dramatically shifting patterns of alternative splicing lasting at least a month. We connect our functional enrichment and alternative splicing analysis with changes in the extracellular matrix, synaptic physiology, and intrinsic physiology in parvalbumin interneurons days to a week after psychedelic treatment. Our dataset is an essential resource for understanding the persistent, cell type-specific effects of psychedelics on cortical cell types and functions.

24 February 2026 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
EAElio Adib
Elio Adib
Amin NassarAmin Nassar
Amin Nassar
SASarah Abou Alaiwi
Sarah Abou Alaiwi
SBSylvan C. Baca
Sylvan C. Baca
THTimothy Hanlon
Timothy Hanlon
MFMatthew Freedman
Matthew Freedman
We generated 64 epigenomic datasets using chromatin immunoprecipitation with sequencing and assay for transposase-accessible chromatin sequencing profiling on 28 fresh bladder cancer specimens of luminal and basal-squamous expression subtypes. An integrated analysis of core regulatory circuitry, enhancer activity, and transcription factor (TF) expression specificity nominated 23 luminal-specific and 14 basal-squamous–specific candidate master TFs (MTF), including established regulators like FOXA1, PPARG, and GATA3 for luminal bladder cancer and TP63 for basal-squamous bladder cancer, as well as new basal-squamous MTF candidates, SNAI2 and CEBPB. GRHL2, a regulator of subtype differentiation, was identified as a common MTF to luminal and basal-squamous bladder cancers. Cis-regulatory elements were enriched up to 80-fold for bladder cancer risk variants. Keratinization pathways were enriched in genetically determined basal-squamous sites, whereas carcinogen glucuronidation pathways were enriched in luminal sites. Integrating germline variation and epigenomics through a cistrome-wide association study identified a new bladder cancer risk locus upstream of SPINK1 and linked 10 of 19 bladder cancer risk loci to regulatory elements from a 350,000-sample genome-wide association study. Implications: Overall, this integrative computational analysis provides comprehensive insights into the epigenomic underpinnings of bladder cancer subtypes, nominates candidate master regulators of cellular identity for future experimental validation, and reveals how regulatory elements harboring inherited germline variation may contribute to bladder cancer risk and biology.

23 June 2017 in bioRxiv
Verified
Preprint
Open access
PDF file
Marcos Abraao De Souza FonsecaMarcos Abraao De Souza Fonseca
Marcos Abraao De Souza Fonseca
RVRicardo Z. N. Vêncio
Ricardo Z. N. Vêncio
Background: In addition to the regulatory elements already known, for instance, transcription factors or post-translation modifications, there is growing interest in the regulatory role played by non-coding RNA molecules (ncRNA), whose functions are performed at a different level of biological information processing. Model organisms provide a convenient way of working in the laboratory, and different research groups use these models to conduct studies on the cellular mechanisms present in these organisms. Although some ncRNAs elements have been found in the Halobacterium salinarum model organism, we believe that not enough is known about these genomic regions. Methods: Therefore, an in silico analysis for ncRNA identification was conducted on H. salinarum NRC-1. Considering a data integration perspective and some available methodologies, several machine learning models were built and used to designate candidate ncRNAs genome regions. Results: A total of 42 new ncRNAs were identified. Combing analysis with other available tools, it had been observed that some suggested candidates also was found with different methodologies and thus, it highlights the proposed results.